FeesSafety
Pluang+

DeFi Technologies to release Q3 2026 financials and host shareholder call on Nov 13.

Company Fundamentals
04 Nov 2026, 14:30 WIB
PRNewsWire
View Source
Neutral
DeFi Technologies to release Q3 2026 financials and host shareholder call on Nov 13.

DeFi Technologies Inc. announced it will release its financial results for Q3 2026 after market close on November 12, 2026. The company will hold a shareholder call on November 13, 2026, at 11:00 a.m. EST to discuss its financial performance. DeFi Technologies operates in the digital asset space, bridging traditional finance and decentralized finance through its subsidiaries like Valour and Stillman Digital. This update is important for investors tracking the company's progress in the growing digital asset market.

DeFi Technologies announced a shareholder call to discuss its Q3 2026 financial results. For readers following the US stock market on Pluang, here is a snapshot as of Nov 04, 2026 19:11 WIB: out of 150 priced US stocks, 125 rose and 23 fell. Notable movers include Snowflake Inc (SNOW) at USD 281.32 with a 1-day change of -4.65%, Marqeta Inc (MQ) at USD 17.00 down 4.49%, and Palantir Technologies Inc (PLTR) at USD 167.82 down 4.32%.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
26 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
26 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
26 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
26 minutes ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
26 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App